Novartis Stock - Jefferies reiterates Hold rating

Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/18/2026, 17:20 CET. Details in the imprint.

Novartis (CH0012005267) sits under renewed analyst scrutiny after a recent Jefferies research note. The US investment bank reiterated its Hold rating and kept the price target at CHF 110 for the Swiss pharma stock, according to a DPA-AFX summary of the report.

What Jefferies highlights

The Jefferies update keeps Novartis at Hold with an unchanged CHF 110 price target, signaling a neutral stance after the stock’s recent performance in Zurich. The brief note mentions Novartis next to other large European pharma names in a sector-level review.

The rating reiteration follows a period in which Novartis has tightened its focus on innovative medicines, including oncology and cardiovascular drugs, after spinning off its Sandoz generics unit in 2023, as outlined in company materials on its strategy. The Novartis Investor Relations pages detail management’s emphasis on higher-margin innovative therapies.

How consensus on Novartis stands

Against the Jefferies Hold stance, broader analyst consensus on Novartis remains mixed, with a spread of Buy, Hold and Sell recommendations across the major broker houses. Aggregated data from financial portals show a clustered range of price targets not far from current trading levels.

Consensus estimates factor in mid-single-digit annual sales growth over the next few years as key growth drivers, such as cardiovascular drug Entresto and multiple sclerosis therapy Kesimpta, offset patent expiries and price pressure in mature products, according to recent broker research round-ups on major financial information platforms. MarketWatch analyst estimate compilations reflect these assumptions.

How the company makes money

Novartis generates the bulk of its revenue from patented prescription medicines in areas such as oncology, cardiovascular, immunology, neuroscience and ophthalmology. Flagship products include heart-failure drug Entresto, eye treatment Lucentis and immunology therapy Cosentyx, each contributing materially to group sales in recent years.

Where the stock trades today

Novartis shares (CH0012005267) trade on SIX Swiss Exchange at CHF 128.60 as of 06/18/2026, 17:20 CET.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.